Literature DB >> 28933796

[Diagnostic and therapeutic approach to chronic inflammatory enteropathies in dogs].

Carolin Erdmann1, Romy M Heilmann.   

Abstract

Entities:  

Keywords:  CCECAI) have been established in dogs; Chronic enteropathy; and abdominal pain. Clinicopathologic parameters; and diagnostic imaging findings are important to exclude other (e.g.; and has been shown to display a worse prognosis. PLE can be induced by severe intestinal inflammation; antibiotic-responsive enteropathy (ARE); based on the response to empirical treatment. The term protein-losing enteropathy (PLE) is used for a subgroup of affected dogs with intestinal protein loss; borborygm; can help to evaluate the patient for gastrointestinal disease and to determine the disease location (distal vs. proximal small intestine). Chronic inflammatory enteropathies are retrospectively classified as food-responsive enteropathy (FRE); diarrhea; fecal examination; food-responsive diarrhea; immunosuppressant-responsive enteropathy Chronic enteropathies are characterized by persistent or recurrent gastrointestinal signs for a minimum duration of 3 weeks. Clinical signs for chronic enteropathies include vomiting; immunosuppressant-responsive or -refractory enteropathy (IRE); including the determination of the serum cobalamin and folate concentrations; infectious or obstructive) gastrointestinal and extra-gastrointestinal etiologies. Specific diagnostic tests; inflammatory bowel disease; neoplasia; or non-responsive enteropathy (NRE); or primary intestinal lymphangiectasia. Clinical scoring systems (CIBDAI; weight loss; whereas the response to treatment varies in dogs with IRE or PLE; which can be applied to objectively assess the severity of clinical signs at the time of diagnosis and to monitor patient improvement during treatment. The prognosis in dogs with chronic enteropathy depends on the underlying etiopathogenesis. Dogs diagnosed with FRE typically respond favorably and display good long-term control with appropriate dietary management; with frequent relapses of clinical signs.

Mesh:

Year:  2017        PMID: 28933796     DOI: 10.15654/TPK-170366

Source DB:  PubMed          Journal:  Tierarztl Prax Ausg K Kleintiere Heimtiere        ISSN: 1434-1239            Impact factor:   0.596


× No keyword cloud information.
  6 in total

1.  Association between serum soluble receptor for advanced glycation end-products (RAGE) deficiency and severity of clinicopathologic evidence of canine chronic inflammatory enteropathy.

Authors:  Angela Isabel Cabrera-García; Jan S Suchodolski; Jörg M Steiner; Romy M Heilmann
Journal:  J Vet Diagn Invest       Date:  2020-07-27       Impact factor: 1.279

2.  Blood neutrophil-to-lymphocyte ratio (NLR) as a diagnostic marker in dogs with chronic enteropathy.

Authors:  Anja Becher; Jan S Suchodolski; Jörg M Steiner; Romy M Heilmann
Journal:  J Vet Diagn Invest       Date:  2021-02-08       Impact factor: 1.279

3.  Association of fecal calprotectin concentrations with disease severity, response to treatment, and other biomarkers in dogs with chronic inflammatory enteropathies.

Authors:  Romy M Heilmann; Nora Berghoff; Joanne Mansell; Niels Grützner; Nolie K Parnell; Corinne Gurtner; Jan S Suchodolski; Jörg M Steiner
Journal:  J Vet Intern Med       Date:  2018-02-20       Impact factor: 3.333

4.  Comparison of the systemic phospholipid profile in dogs diagnosed with idiopathic inflammatory bowel disease or food-responsive diarrhea before and after treatment.

Authors:  Katja Kalenyak; Romy M Heilmann; Chris H A van de Lest; Jos F Brouwers; Iwan A Burgener
Journal:  PLoS One       Date:  2019-04-16       Impact factor: 3.240

Review 5.  Canine chronic enteropathy-Current state-of-the-art and emerging concepts.

Authors:  Albert E Jergens; Romy M Heilmann
Journal:  Front Vet Sci       Date:  2022-09-21

Review 6.  Clinical utility of currently available biomarkers in inflammatory enteropathies of dogs.

Authors:  Romy M Heilmann; Jörg M Steiner
Journal:  J Vet Intern Med       Date:  2018-09-17       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.